Navigation Links
Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
Date:3/3/2008

>This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS031291, a product candidate from its chemokine receptor CCR1 program, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, PS178990 and PS031291, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Schering-Plough and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milest
'/>"/>
SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
2. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
3. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
4. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
5. Pharmacopeia Announces Third Quarter 2007 Financial Results
6. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
7. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
8. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LONDON , December 24, 2014 ... grow at an average rate of 8.1%. The US ... Hip, knee and spine surgeries are the common orthopedic ... they have a lower penetration. Increased number of product ... composites. Non-metallic orthopedic devices have gained popularity in the ...
(Date:12/24/2014)... DALLAS , December 24, 2014 /PRNewswire/ ... Research Report on Global Disposable Syringe Industry ... to its online business intelligence library. ... Global Disposable Syringe Industry is a professional ... Syringe market.  For overview analysis, the report ...
(Date:12/24/2014)... China , Dec. 23, 2014 ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today announced that the Company ... its Good Manufacturing Practice (GMP) certificate of TPI,s ... Drug Administration,s (CFDA). The public notice period is ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
... options and research directions , , WASHINGTON, June ... therapeutic option for many patients with interstitial cystitis (IC). IC ... 8 million women and 1.5 million men in the United ... noticed a correlation between allergies and IC. Recently, a urologist ...
... Families of Spinal Muscular Atrophy has just released details ... funded therapeutic pipeline. , , Families of SMA ... Quinazolines to boost gene expression; 2) Tetracyclines at Paratek ... replacement program at California Stem Cell and UCI. ...
Cached Medicine Technology:Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 2Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 3Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 4Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs 2Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs 3
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... of youth" drug that can delay the effects of aging ... suggests. Seniors received a significant boost to their immune ... pathway linked to aging and immune function, researchers with the ... a version of the drug rapamycin, improved the seniors, immune ...
(Date:12/25/2014)... Carolina (PRWEB) December 25, 2014 ... Carolina Retirement Community, recently showed their generous spirit ... of the Catawba County Parenting Network- Grandparents Raising ... 10 children gathered around the largest Christmas tree ... open presents purchased by residents of the Abernethy ...
(Date:12/24/2014)... finds applications in a large number of fields of ... and research for metabolic and genetic disorders. It is ... techniques for the discovery and development of cancer biomarkers. ... growing worldwide. In 2012, there were 14.1 million new ... people living with cancer (within five years of diagnosis) ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Dr. Vu ... the expansion of his practice and med-spa with the ... practice’s growing list of cosmetic treatments and services. , ... into the skin,” says Dr. Ho. “As a result ... such as wrinkles, sun spots, discolorations or blemishes.” , ...
(Date:12/24/2014)... 2014 Mike Billings , PT, ... Derek Fenwick, PT, MBA, GCS, Director of Professional ... from the passing of the Improving Medicare Post-Acute ... this taping of the Infinicast, the two leaders discuss ... Social Security Act to standardize post-acute assessment data for ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2
... the community-based model of directly observed therapy (DOT) ... improves patient survival. This is according to researchers ... Health, in collaboration with colleagues at University of ... randomized controlled trial of patient-nominated treatment-supporters providing partial ...
... CORVALLIS, Ore. Researchers have discovered a new strain ... and effectively help degrade polycyclic aromatic hydrocarbons, or PAHs ... harmful aspects of oil spills. Because of its ... considerable value in the long-term cleanup of the massive ...
... half of patients hospitalized with bipolar disorder may suffer ... with the psychiatric condition the more likely they are ... Michigan State University study. The study, led by ... bipolar disorder, a condition sometimes called manic-depressive disorder and ...
... belong to a youth club, they gain a stronger sense ... University study has revealed. The study suggests that even ... keeping children out of trouble. "The more kids participate ... Dawn Anderson-Butcher, an associate professor of social work at Ohio ...
... INDIANAPOLIS The Indiana Network for Patient Care (INPC), ... the United States, is expanding to include post-acute care ... to a growing number of individuals who often have ... facilities, part of Golden Living, the leading provider of ...
... -- The combination of decitabine and carboplatin appears to improve ... an upcoming issue of the journal Cancer (online ... participated in a phase I clinical trial had no disease ... resolution of tumor tissue for a period of time. ...
Cached Medicine News:Health News:Directly observed HIV treatment by patient-nominated treatment supporter improves survival 2Health News:New strain of bacteria discovered that could aid in oil spill, other environmental cleanup 2Health News:New strain of bacteria discovered that could aid in oil spill, other environmental cleanup 3Health News:MSU researcher identifies links between hypertension, bipolar disorders 2Health News:Youth clubs strengthen kids' self image to keep them out of trouble 2Health News:Youth clubs strengthen kids' self image to keep them out of trouble 3Health News:Improving care for older adults 2Health News:Improving care for older adults 3Health News:Late-stage ovarian cancer shows promise in 2-drug phase I trial 2Health News:Late-stage ovarian cancer shows promise in 2-drug phase I trial 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: